Chardan analyst Geulah Livshits lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $8 from $9 and keeps a Buy rating on the shares after the company announced data from the RIDGE-1 trial of TN-401 in PKP2-ACM. With this readout, Tenaya remains “very much in the competitive mix” for PKP2-ACM along with peers Lexeo Therapeutics (LXEO) and Rocket Pharmaceuticals (RCKT), both of which will also be providing updates on their respective programs over 2026, says the analyst, who updated the firm’s model to reflect dilution from Tenaya’s announced stock offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Tenaya Therapeutics 50M share Spot Secondary priced at $1.20
- FDA Lifts Hold on Tenaya’s MyPEAK-1 Trial
- Tenaya Therapeutics files to sell common stock, no amount given
- Tenaya Therapeutics announces interim data from cohort one of RIDGE-1 trial
- Tenaya Therapeutics announces clinical hold on MyPEAK-1 trial lifted by FDA